In the matter of Recce Pharmaceuticals Ltd

Link copied
Case Copied 12 min read

Supreme Court


New South Wales

Medium Neutral Citation: In the matter of Recce Pharmaceuticals Ltd [2021] NSWSC 1316
Hearing dates: 12 October 2021
Date of orders: 12 October 2021
Decision date: 12 October 2021
Jurisdiction:Equity - Corporations List
Before: Black J
Decision:

Orders made in accordance with paragraphs 1-8 of the Originating Process filed on 11 October 2021.

Catchwords:

CORPORATIONS LAW — Securities — Application for orders extending the period for issuing cleansing notices under s 708A of the Corporations Act 2001 (Cth) — Securities issued without valid cleansing notice — Where failure to issue cleansing notice was an honest and inadvertent error — Other orders made under s 1322 of the Corporations Act 2001 (Cth).

Legislation Cited:

- Corporations Act 2001 (Cth), ss 707, 708A, 1322

Cases Cited:

- Re Airtasker Limited [2021] NSWSC 629

- Re Austpac Resources NL [2010] NSWSC 1438

- Re Golden Gate Petroleum Ltd (2010) 77 ACSR 17; [2010] FCA 40

- Re Imdex Ltd [2020] WASC 298

- Re Kollakorn Corporation Ltd [2020] NSWSC 1549

- Re Pilbara Minerals Ltd [2021] WASC 330

Category:Principal judgment
Parties: Reece Pharmaceuticals Ltd (Plaintiff)
Representation:

Counsel:
G Sirtes SC/A Smorchevsky (Plaintiff)

Solicitors:
Automic Legal Pty Ltd (Plaintiff)
File Number(s): 2021/288717

Judgment – ex tempore (Revised 12 October 2021)

Background

  1. By Originating Process filed on 11 October 2021, the Plaintiff, Recce Pharmaceuticals Ltd (“Recce”) applies for orders validating any sales or offers of sale of certain shares without disclosure under s 707 of the Corporations Act 2001 (Cth) and associated orders under s 1322(4) of the Act, in circumstances that it issued 10,000 ordinary fully paid shares on 2 September 2021 without issuing a cleansing notice under s 708A of the Corporations Act. It also seeks associated orders under 1322 of the Act, directed, in effect, to validating the issue and preserving the ability of shareholders to rely on exemptions from disclosure in respect of subsequent sales of their shares. The issues arising in this case are of the kind that have arisen in several earlier cases, including Re Golden Gate Petroleum Ltd (2010) 77 ACSR 17; [2010] FCA 40, Re Kollakorn Corporation Ltd [2020] NSWSC 1549 and Re Airtasker Ltd [2021] NSWSC 629.

Affidavit evidence

  1. Recce relies on several affidavits, which provide a comprehensive account of relevant events. Recce relies on the affidavit dated 11 October 2021 of Mr McKeough, who is the solicitor acting for Recce in this application and also has involvement with the Automic Group of companies which provides, broadly, company secretarial services to Recce. Mr McKeough notes that Recce is an Australian public company listed on the Australian Securities Exchange (“ASX”) which had, between 8 and 12 October 2021, a share capitalisation in the range $159-$161.6 million. Its shares have been listed on ASX since 15 January 2016 and it operates in the pharmaceuticals, biotechnology and life sciences sector. Mr McKeough is Recce's company secretary, although he is assisted by staff in the Automic…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read In the matter of Recce Pharmaceuticals Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] NSWSC 1316
Decision Date

CaseChat Overview and Summary

Recce Pharmaceuticals Ltd applied to the Federal Court for an extension of time to issue cleansing notices under section 708A of the Corporations Act 2001 (Cth) in relation to securities issued without such notices. The company sought to correct an oversight where the cleansing notices were not issued within the statutory timeframe due to an honest and inadvertent error. The court was required to determine whether the failure to issue the notices was indeed an honest and inadvertent error, and if so, whether it was in the interests of justice to grant the extension.

The court considered the statutory provisions of section 708A and noted that the primary purpose of the requirement for a cleansing notice is to protect investors and ensure transparency in securities transactions. The court held that the failure to issue the notice was indeed an honest and inadvertent error. The company had acted promptly upon discovering the oversight and demonstrated a commitment to rectifying the situation. The court also took into account the lack of prejudice to the investors and the company's efforts to comply with its statutory obligations.

The court granted the application for an extension of time to issue the cleansing notices and made additional orders under section 1322 of the Corporations Act 2001 (Cth) to ensure that Recce Pharmaceuticals Ltd complied with its obligations going forward. The court ordered that the company issue the cleansing notices within a specified period and take steps to ensure that such errors did not occur in the future. The court's decision balanced the need to protect investors with the recognition of the company's honest mistake and its efforts to rectify the situation.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established